Patents by Inventor Luke S. S. Guo

Luke S. S. Guo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240000764
    Abstract: Provided is an anesthetic composition for locally administrating an amide-type anesthetic into a subject in need thereof. The anesthetic composition has multilamellar vesicles with entrapped amide-type anesthetic prepared by hydrating a highly entrapped lipid structure comprising an amide-type anesthetic and a lipid mixture with an aqueous buffer solution at a pH higher than 5.5. Also provided is a method to prepare an anesthetic composition using a simpler and more feasible process for large-scale manufacture and for providing a high molar ratio of amide-type anesthetic to phospholipid content as compared to the prior art. This anesthetic composition has a prolonged duration of efficacy adapted to drug delivery.
    Type: Application
    Filed: September 13, 2023
    Publication date: January 4, 2024
    Inventors: Keelung HONG, Hao-Wen KAO, Yi-Yu LIN, Luke S.S. GUO
  • Patent number: 11793755
    Abstract: The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.
    Type: Grant
    Filed: January 5, 2021
    Date of Patent: October 24, 2023
    Assignees: TAIWAN LIPOSOME CO., LTD., TLC BIOPHARMACEUTICALS, INC.
    Inventors: Keelung Hong, Luke S. S. Guo, Yun-Long Tseng, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hui Lin
  • Patent number: 11793799
    Abstract: Provided is an anesthetic composition for locally administrating an amide-type anesthetic into a subject in need thereof. The anesthetic composition has multilamellar vesicles with entrapped amide-type anesthetic prepared by hydrating a highly entrapped lipid structure comprising an amide-type anesthetic and a lipid mixture with an aqueous buffer solution at a pH higher than 5.5. Also provided is a method to prepare an anesthetic composition using a simpler and more feasible process for large-scale manufacture and for providing a high molar ratio of amide-type anesthetic to phospholipid content as compared to the prior art. This anesthetic composition has a prolonged duration of efficacy adapted to drug delivery.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: October 24, 2023
    Assignees: TLC Biopharmaceuticals Inc., Taiwan Liposome Co., Ltd.
    Inventors: Keelung Hong, Hao-Wen Kao, Yi-Yu Lin, Luke S. S. Guo
  • Patent number: 11771766
    Abstract: An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: October 3, 2023
    Assignees: Taiwan Liposome Co., Ltd., TLC Biopharmaceuticals, Inc.
    Inventors: Sheue-Fang Shih, Po-Chun Chang, Yun-Long Tseng, Luke S. S. Guo, Keelung Hong
  • Publication number: 20210145744
    Abstract: The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.
    Type: Application
    Filed: January 5, 2021
    Publication date: May 20, 2021
    Inventors: KEELUNG HONG, LUKE S. S. GUO, YUN-LONG TSENG, SHEUE-FANG SHIH, PO-CHUN CHANG, CHIH-CHIANG TSAI, HONG-HUI LIN
  • Patent number: 10959951
    Abstract: The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: March 30, 2021
    Assignees: TAIWAN LIPOSOME CO., LTD., TLC BIOPHARMACEUTICALS, INC.
    Inventors: Keelung Hong, Luke S. S. Guo, Yun-Long Tseng, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hui Lin
  • Publication number: 20200289652
    Abstract: An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes.
    Type: Application
    Filed: April 30, 2020
    Publication date: September 17, 2020
    Inventors: Sheue-Fang SHIH, Po-Chun CHANG, Yun-Long TSENG, Luke S.S. GUO, Keelung HONG
  • Publication number: 20200276123
    Abstract: The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.
    Type: Application
    Filed: May 15, 2020
    Publication date: September 3, 2020
    Inventors: KEELUNG HONG, LUKE S. S. GUO, YUN-LONG TSENG, SHEUE-FANG SHIH, PO-CHUN CHANG, CHIH-CHIANG TSAI, HONG-HUI LIN
  • Patent number: 10736846
    Abstract: The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: August 11, 2020
    Assignees: TAIWAN LIPOSOME CO., LTD., TCL BIOPHARMACEUTICALS, INC.
    Inventors: Keelung Hong, Luke S. S. Guo, Yun-Long Tseng, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hui Lin
  • Publication number: 20200188374
    Abstract: Provided is an anesthetic composition for locally administrating an amide-type anesthetic into a subject in need thereof. The anesthetic composition has multilamellar vesicles with entrapped amide-type anesthetic prepared by hydrating a highly entrapped lipid structure comprising an amide-type anesthetic and a lipid mixture with an aqueous buffer solution at a pH higher than 5.5. Also provided is a method to prepare an anesthetic composition using a simpler and more feasible process for large-scale manufacture and for providing a high molar ratio of amide-type anesthetic to phospholipid content as compared to the prior art. This anesthetic composition has a prolonged duration of efficacy adapted to drug delivery.
    Type: Application
    Filed: August 28, 2018
    Publication date: June 18, 2020
    Inventors: Keelung HONG, Hao-Wen KAO, Yi-Yu LIN, Luke S.S. GUO
  • Patent number: 10660960
    Abstract: An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: May 26, 2020
    Assignees: TAIWAN LIPOSOME CO., LTD., TLC BIOPHARMACEUTICALS, INC.
    Inventors: Sheue-Fang Shih, Po-Chun Chang, Yun-Long Tseng, Luke S. S. Guo, Keelung Hong
  • Publication number: 20190290583
    Abstract: The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.
    Type: Application
    Filed: June 12, 2019
    Publication date: September 26, 2019
    Inventors: KEELUNG HONG, LUKE S. S. GUO, YUN-LONG TSENG, SHEUE-FANG SHIH, PO-CHUN CHANG, CHIH-CHIANG TSAI, HONG-HUI LIN
  • Patent number: 10350294
    Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid, derivative thereof, a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5 umol per 50 ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: July 16, 2019
    Assignees: TAIWAN LIPOSOME COMPANY, LTD., TLC BIOPHARMACEUTICALS, INC.
    Inventors: Keelung Hong, Luke S. S. Guo, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hul Lin, Yun-Long Tseng
  • Patent number: 10322086
    Abstract: The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: June 18, 2019
    Assignees: TLC BIOPHARMACEUTICALS, INC., TAIWAN LIPOSOME COMPANY, LTD.
    Inventors: Keelung Hong, Luke S. S. Guo, Yun-Long Tseng, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hui Lin
  • Patent number: 10286076
    Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid, derivative thereof, a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5 umol per 50 ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: May 14, 2019
    Assignees: TAIWAN LIPOSOME COMPANY, LTD., TLC BIOPHARMACEUTICALS, INC.
    Inventors: Keelung Hong, Luke S. S. Guo, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hul Lin, Yun-Long Tseng
  • Patent number: 10058616
    Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid, derivative thereof a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5 umol per 50 ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.
    Type: Grant
    Filed: February 8, 2013
    Date of Patent: August 28, 2018
    Assignees: TLC BIOPHARMACEUTICALS, INC., TAIWAN LIPOSOME COMPANY, LTD.
    Inventors: Keelung Hong, Luke S. S. Guo, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hul Lin, Yun-Long Tseng
  • Publication number: 20180193461
    Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid, derivative thereof, a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5 umol per 50 ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.
    Type: Application
    Filed: March 6, 2018
    Publication date: July 12, 2018
    Inventors: Keelung Hong, Luke S. S. Guo, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hul Lin, Yun-Long Tseng
  • Publication number: 20180169248
    Abstract: An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes.
    Type: Application
    Filed: February 5, 2018
    Publication date: June 21, 2018
    Inventors: SHEUE-FANG SHIH, PO-CHUN CHANG, YUN-LONG TSENG, LUKE S.S. GUO, KEELUNG HONG
  • Patent number: 9987360
    Abstract: An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: June 5, 2018
    Assignees: TAIWAN LIPOSOME CO. LTD., TLC BIOPHARMACEUTICALS, INC.
    Inventors: Sheue-Fang Shih, Po-Chun Chang, Yun-Long Tseng, Luke S. S. Guo, Keelung Hong
  • Publication number: 20170367979
    Abstract: The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.
    Type: Application
    Filed: September 5, 2017
    Publication date: December 28, 2017
    Inventors: KEELUNG HONG, LUKE S. S. GUO, YUN-LONG TSENG, SHEUE-FANG SHIH, PO-CHUN CHANG, CHIH-CHIANG TSAI, HONG-HUI LIN